Use of bivalirudin to treat heparin-induced thrombocytopenia in a patient with idiopathic giant-cell myocarditis.
Giant-cell myocarditis (GCM) is a rare, idiopathic disorder of young adults with high rates of morbidity and mortality. We describe a unique case of giant cell myocarditis associated with heparin-induced thrombocytopenia and thrombosis syndrome (HITTS). Our patient responded to therapy with bivalirudin, but later succumbed to complications from multiorgan failure. To our knowledge, this is the first reported case of GCM associated with HITTS, which was treated with bivalirudin (Angiomax; The Medicines Company; Parsippany, NJ).
Alekshun
Todd J
TJ
H Lee Moffitt Cancer Center and Research Institute, The University of South Florida, Tampa, USA.
Lundbye
Justin
J
Sokol
Lubomir
L
Dailey
Mark E
ME
D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use*; D017809:Fatal Outcome; D015726:Giant Cells / Q000473:pathology*; D006493:Heparin / Q000009:adverse effects*; D006629:Hirudins; D006801:Humans; D008297:Male; D009102:Multiple Organ Failure; D009205:Myocarditis / Q000150:complications / Q000473:pathology*; D009336:Necrosis; D010446:Peptide Fragments / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced / Q000188:drug therapy*; D013927:Thrombosis / Q000150:complications / Q000188:drug therapy
D000925:Anticoagulants; D006629:Hirudins; D010446:Peptide Fragments; D011994:Recombinant Proteins; D006493:Heparin; C074619:bivalirudin